Loading
Obesity Prevention / Obesity · Journal article
Food Microbiology · June 27, 2026
Encouraging direction, but not yet definitive.
This preclinical study in a small-litter overfeeding mouse model demonstrates that oral FBA-40 (Bifidobacterium animalis DPU-MWFBA) attenuates obesity, improves glucose and lipid metabolism, and restores intestinal barrier and hepatic function through coordinated changes in microbiota composition and gene expression. The evidence is mechanistic and promising but remains in an animal model without human validation or comparison of FBA-40 to standard or alternative interventions.
Preclinical mechanistic study in a controlled early-overfeeding mouse model. Mice subjected to early-life nutritional overfeeding via small-litter rearing. Intervention: Bifidobacterium animalis DPU-MWFBA (designated FBA-40), oral administration.
FBA-40 significantly attenuated excessive body weight gain and adiposity in early-overfed mice FBA-40 improved glucose tolerance and insulin sensitivity, and alleviated dyslipidemia, systemic inflammation, and hepatic dysfunction FBA-40 preserved intestinal barrier integrity by increasing ZO-1 and Occludin expression while suppressing TNF-α-associated inflammatory activation
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This work identifies FBA-40 as a candidate probiotic mechanism for early-life obesity prevention but requires translation to human studies before clinical recommendation. Clinicians should note this represents preliminary mechanistic evidence in animals, not proof of efficacy or safety in human infants.
Mechanistic preclinical study in a mouse model showing FBA-40 attenuates obesity and metabolic dysfunction via multiple pathways, but lacks human evidence and clinical endpoints.
As stated by the source record.
Quoted from the source exactly as published.
This work identifies FBA-40 as a candidate probiotic mechanism for early-life obesity prevention but requires translation to human studies before clinical recommendation. Clinicians should note this represents preliminary mechanistic evidence in animals, not proof of efficacy or safety in human infants.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Early-life nutritional overfeeding is increasingly recognized as a critical driver of metabolic programming and long-term obesity risk. This study investigated the protective effects and underlying mechanisms of Bifidobacterium animalis DPU-MWFBA, designated as FBA-40, against early-life overfeeding-induced obesity and metabolic dysfunction. An early overfeeding mouse model was established by small-litter rearing, followed by a two-week oral intervention with FBA-40. FBA-40 significantly attenuated excessive body weight gain and adiposity, improved glucose tolerance and insulin sensitivity, and alleviated dyslipidemia, systemic inflammation, and hepatic dysfunction. Histological analyses showed that FBA-40 reduced hepatic lipid accumulation and improved liver morphology. In addition, colonic histology and immunohistochemistry demonstrated that FBA-40 preserved intestinal barrier integrity by increasing ZO-1 and Occludin expression while suppressing TNF-α-associated inflammatory activation. Gut microbiota analysis revealed that FBA-40 restored microbial richness and diversity and reshaped gut microbial composition toward a more metabolically favorable profile. Hepatic transcriptomic analysis further showed that FBA-40 reprogrammed lipid metabolism-, oxidative stress-, and inflammation-related pathways, particularly PPAR signaling, linoleic acid metabolism, cholesterol metabolism, bile secretion, and arachidonic acid metabolism. qRT-PCR and estern blot validation confirmed that FBA-40 suppressed lipogenesis-related targets, including Scd1, Acaca, Lpin1, and SCD1, while restoring PPARα/EHHADH-associated fatty acid β-oxidation and GPX1-mediated antioxidant defense. Collectively, these findings demonstrate that FBA-40 alleviates early-life overfeeding-induced metabolic dysfunction by coordinating gut microbial remodeling, intestinal barrier protection, and hepatic lipid metabolic reprogramming. This study provides mechanistic evidence supporting FBA-40 as a promising early-life probiotic candidate for preventing obesity and associated metabolic disorders.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.